Panacea Biotec Limited

NSEI:PANACEABIO Stock Report

Market Cap: ₹20.6b

Panacea Biotec Balance Sheet Health

Financial Health criteria checks 5/6

Panacea Biotec has a total shareholder equity of ₹8.3B and total debt of ₹215.7M, which brings its debt-to-equity ratio to 2.6%. Its total assets and total liabilities are ₹12.4B and ₹4.1B respectively.

Key information

2.6%

Debt to equity ratio

₹215.70m

Debt

Interest coverage ration/a
Cash₹1.77b
Equity₹8.29b
Total liabilities₹4.14b
Total assets₹12.43b

Recent financial health updates

Is Panacea Biotec (NSE:PANACEABIO) A Risky Investment?

Dec 24
Is Panacea Biotec (NSE:PANACEABIO) A Risky Investment?

Does Panacea Biotec (NSE:PANACEABIO) Have A Healthy Balance Sheet?

Jun 05
Does Panacea Biotec (NSE:PANACEABIO) Have A Healthy Balance Sheet?

Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

Sep 17
Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

Recent updates

Is Panacea Biotec (NSE:PANACEABIO) A Risky Investment?

Dec 24
Is Panacea Biotec (NSE:PANACEABIO) A Risky Investment?

There's No Escaping Panacea Biotec Limited's (NSE:PANACEABIO) Muted Revenues Despite A 34% Share Price Rise

Nov 22
There's No Escaping Panacea Biotec Limited's (NSE:PANACEABIO) Muted Revenues Despite A 34% Share Price Rise

There's No Escaping Panacea Biotec Limited's (NSE:PANACEABIO) Muted Revenues Despite A 40% Share Price Rise

Oct 03
There's No Escaping Panacea Biotec Limited's (NSE:PANACEABIO) Muted Revenues Despite A 40% Share Price Rise

Most Shareholders Will Probably Find That The Compensation For Panacea Biotec Limited's (NSE:PANACEABIO) CEO Is Reasonable

Sep 21
Most Shareholders Will Probably Find That The Compensation For Panacea Biotec Limited's (NSE:PANACEABIO) CEO Is Reasonable

Panacea Biotec Limited (NSE:PANACEABIO) Held Back By Insufficient Growth Even After Shares Climb 25%

Aug 19
Panacea Biotec Limited (NSE:PANACEABIO) Held Back By Insufficient Growth Even After Shares Climb 25%

Does Panacea Biotec (NSE:PANACEABIO) Have A Healthy Balance Sheet?

Jun 05
Does Panacea Biotec (NSE:PANACEABIO) Have A Healthy Balance Sheet?

Why Investors Shouldn't Be Surprised By Panacea Biotec Limited's (NSE:PANACEABIO) Low P/S

Apr 04
Why Investors Shouldn't Be Surprised By Panacea Biotec Limited's (NSE:PANACEABIO) Low P/S

Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All

Sep 23
Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All

Estimating The Fair Value Of Panacea Biotec Limited (NSE:PANACEABIO)

Jul 28
Estimating The Fair Value Of Panacea Biotec Limited (NSE:PANACEABIO)

How Does Panacea Biotec's (NSE:PANACEABIO) CEO Pay Compare With Company Performance?

Feb 14
How Does Panacea Biotec's (NSE:PANACEABIO) CEO Pay Compare With Company Performance?

Introducing Panacea Biotec (NSE:PANACEABIO), A Stock That Climbed 80% In The Last Five Years

Jan 06
Introducing Panacea Biotec (NSE:PANACEABIO), A Stock That Climbed 80% In The Last Five Years

Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

Sep 17
Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

If You Had Bought Panacea Biotec (NSE:PANACEABIO) Stock A Year Ago, You Could Pocket A 78% Gain Today

Aug 03
If You Had Bought Panacea Biotec (NSE:PANACEABIO) Stock A Year Ago, You Could Pocket A 78% Gain Today

Financial Position Analysis

Short Term Liabilities: PANACEABIO's short term assets (₹5.0B) exceed its short term liabilities (₹3.3B).

Long Term Liabilities: PANACEABIO's short term assets (₹5.0B) exceed its long term liabilities (₹863.5M).

Debt to Equity History and Analysis

Debt Level: PANACEABIO has more cash than its total debt.

Reducing Debt: PANACEABIO's debt to equity ratio has reduced from 281.1% to 2.6% over the past 5 years.

Debt Coverage: PANACEABIO's debt is well covered by operating cash flow (114.4%).

Interest Coverage: Insufficient data to determine if PANACEABIO's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/14 06:40
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Panacea Biotec Limited is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.
Amit GuptaBatlivala & Karani Securities India Pvt. Ltd.
Arvind BothraBofA Global Research